Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBIT Margin (2017 - 2025)

UroGen Pharma (URGN) has disclosed EBIT Margin for 9 consecutive years, with 186.23% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 2097.0% year-over-year to 186.23%, compared with a TTM value of 32.14% through Dec 2025, down 58.0%, and an annual FY2025 reading of 32.14%, down 58.0% over the prior year.
  • EBIT Margin was 186.23% for Q4 2025 at UroGen Pharma, up from 99.65% in the prior quarter.
  • Across five years, EBIT Margin topped out at 291.96% in Q4 2021 and bottomed at 348.88% in Q1 2021.
  • Average EBIT Margin over 5 years is 60.5%, with a median of 112.54% recorded in 2022.
  • The sharpest move saw EBIT Margin soared 837326bps in 2021, then crashed -10452bps in 2022.
  • Year by year, EBIT Margin stood at 291.96% in 2021, then crashed by -36bps to 187.44% in 2022, then tumbled by -36bps to 120.32% in 2023, then skyrocketed by 37bps to 165.25% in 2024, then rose by 13bps to 186.23% in 2025.
  • Business Quant data shows EBIT Margin for URGN at 186.23% in Q4 2025, 99.65% in Q3 2025, and 171.17% in Q2 2025.